keyword
MENU ▼
Read by QxMD icon Read
search

prolactin antipsychotic

keyword
https://www.readbyqxmd.com/read/29112461/calcium-and-vitamin-d-supplementation-in-boys-with-risperidone-induced-hyperprolactinemia-a-randomized-placebo-controlled-pilot-study
#1
Chadi A Calarge, James A Mills, Ekhard E Ziegler, Janet A Schlechte
BACKGROUND: The chronic use of antipsychotics has been associated with impaired bone mineralization, partially mediated by hyperprolactinemia. We examined if calcium and vitamin D supplementation promote bone mineral accrual in boys with risperidone-induced hyperprolactinemia. METHODS: Between February 2009 and November 2013, medically healthy, 5- to 17-year-old boys were enrolled in a 36-week double-blind, placebo-controlled study, examining the skeletal effects of supplementation with 1250 mg calcium carbonate and 400 IU of vitamin D3 in risperidone-induced hyperprolactinemia...
November 7, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29097257/a-randomized-13-week-study-assessing-the-efficacy-and-metabolic-effects-of-paliperidone-palmitate-injection-and-olanzapine-in-first-episode-schizophrenia-patients
#2
Manli Huang, Liang Yu, Fen Pan, Shaojia Lu, Shaohua Hu, Jianbo Hu, Jinkai Chen, Pingbo Jin, Hongli Qi, Yi Xu
BACKGROUND: This study was conducted to evaluate the efficacy and metabolic effects of paliperidone palmitate (PP) injections against oral olanzapine in first-episode schizophrenia (FES) patients. METHODS: Eligible patients were randomized to receive PP or olanzapine. Efficacy assessments and weight-related parameters were assessed at baseline, weeks 1, 5, 9, and endpoint or at early withdrawal. Lipid, glucose, insulin and prolactin were evaluated at baseline and endpoint or at early withdrawal...
October 31, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29048190/the-efficacy-and-tolerability-of-paliperidone-in-mania-of-bipolar-disorder-a-preliminary-meta-analysis
#3
Han-Yung Chang, Ping-Tao Tseng, Brendon Stubbs, Che-Sheng Chu, Dian-Jeng Li, Michele Fornaro, Andre Carvalho, Marco Solmi, Nicola Veronese, Eduard Vieta, Tien-Yu Chen, Yen-Wen Chen, Pao-Yen Lin, Philip Chik-Keung Chow
Paliperidone may be effective for the treatment of bipolar disorder (BD); however, the evidence has been mixed. This is the first meta-analysis to evaluate the efficacy, safety, and tolerability of paliperidone for the treatment of BD. We performed a systematic search of the literature using major electronic databases from inception to January 27, 2017. Randomized control trials (RCTs) investigating paliperidone treatment among patients with BD versus a placebo or other second-generation antipsychotics were included...
October 2017: Experimental and Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29017334/brexpiprazole-a-new-leaf-on-the-partial-dopamine-agonist-branch
#4
Judy Hope, David Castle, Nicholas A Keks
OBJECTIVES: Brexpiprazole is a new dopamine partial agonist antipsychotic in the same class as aripiprazole. This paper will briefly review brexpiprazole and compare it with aripiprazole. CONCLUSIONS: Brexpiprazole and aripiprazole are both partial agonists at dopamine D2, and serotonin 5-HT1A and antagonists at serotonin 5-HT2A and noradrenergic α1B receptors. However, the two drugs are significantly different in potencies at various receptors; neurochemical profiles predict that brexpiprazole may be comparable with aripiprazole in its antipsychotic efficacy but may cause less akathisia, extrapyramidal side effects (EPS) and activation...
October 1, 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/28971230/effects-of-2-bromoterguride-a-dopamine-d2-receptor-partial-agonist-on-cognitive-dysfunction-and-social-aversion-in-rats
#5
Emilia Tarland, Robert T Franke, Heidrun Fink, Heinz H Pertz, Jan Brosda
RATIONALE: 2-Bromoterguride, a dopamine D2 receptor partial agonist with antagonist properties at serotonin 5-HT2A receptors and α2C-adrenoceptors, meets the prerequisites of a putative atypical antipsychotic drug (APD). We recently showed that 2-bromoterguride is effective in tests of positive symptoms of schizophrenia in rats without inducing extrapyramidal side effects or metabolic changes. OBJECTIVE: In continuation of our recent work, we now investigated the effect of 2-bromoterguride on apomorphine and phencyclidine (PCP)-induced disruptions of prepulse inhibition (PPI) of the acoustic startle response, a measure of sensory gating...
October 3, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28970469/extrapyramidal-side-effects-of-antipsychotics-are-linked-to-their-association-kinetics-at-dopamine-d2-receptors
#6
David A Sykes, Holly Moore, Lisa Stott, Nicholas Holliday, Jonathan A Javitch, J Robert Lane, Steven J Charlton
Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor. However, support for this hypothesis is limited to a relatively small number of observations made across several decades and under different experimental conditions. Here we show that association rates, but not dissociation rates, correlate with EPS. We measured the kinetic binding properties of a series of typical and atypical APDs in a novel time-resolved fluorescence resonance energy transfer assay, and correlated these properties with their EPS and prolactin-elevating liabilities at therapeutic doses...
October 2, 2017: Nature Communications
https://www.readbyqxmd.com/read/28966250/psychiatric-patients-with-antipsychotic-drug-induced-hyperprolactinemia-and-menstruation-disorders
#7
Kenshi Takechi, Yurika Yoshioka, Hitoshi Kawazoe, Mamoru Tanaka, Shingo Takatori, Miwako Kobayashi, Ichiro Matsuoka, Hiroaki Yanagawa, Yoshito Zamami, Masaki Imanishi, Keisuke Ishizawa, Akihiro Tanaka, Hiroaki Araki
Treatment with antipsychotic drugs has been associated with hyperprolactinemia. The same antipsychotic drugs have also been associated with side effects such as menstruation disorders. The aim of this study was to evaluate the prevalence of hyperprolactinemia and menstruation disorders in women undergoing antipsychotic treatment. We performed a retrospective chart review study of psychiatric patients who underwent laboratory testing for serum prolactin (PRL) level between March 2011 and March 2015 in Ehime University Hospital...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28892416/roman-high-and-low-avoidance-rats-differ-in-their-response-to-chronic-olanzapine-treatment-at-the-level-of-body-weight-regulation-glucose-homeostasis-and-cortico-mesolimbic-gene-expression
#8
Simon S Evers, Gretha J Boersma, Kellie Lk Tamashiro, Anton Jw Scheurink, Gertjan van Dijk
Olanzapine, an antipsychotic agent mainly used for treating schizophrenia, is frequently associated with body weight gain and diabetes mellitus. Nonetheless, studies have shown that not every individual is equally susceptible to olanzapine's weight-gaining effect. Therefore, Roman high and low avoidance rat strains were examined on their responsiveness to olanzapine treatment. The Roman high avoidance rat shares many behavioral and physiological characteristics with human schizophrenia, such as increased central dopaminergic sensitivity, whereas the Roman low avoidance rat has been shown to be prone to diet-induced obesity and insulin resistance...
August 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28839338/metabolic-and-endocrine-profiles-during-1-year-treatment-of-outpatients-with-schizophrenia-with-aripiprazole-lauroxil
#9
Henry A Nasrallah, Ralph Aquila, Arielle D Stanford, Hasan H Jamal, Peter J Weiden, Robert Risinger
BACKGROUND: We assessed long-term metabolic and endocrine profiles of outpatients with schizophrenia participating in a one-year open-label extension study of monthly aripiprazole lauroxil (AL), a long-acting injectable antipsychotic. METHODS: Patients (N = 478) were enrolled in a 52-week, open-label extension study of AL monotherapy administered by intramuscular injection every 4 weeks. Of these, most (368) received AL 882 mg and the remainder AL 441 mg as their fixed-dose regimen...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28838583/oral-aripiprazole-as-maintenance-treatment-in-adolescent-schizophrenia-results-from-a-52-week-randomized-placebo-controlled-withdrawal-study
#10
Christoph U Correll, Eva Kohegyi, Cathy Zhao, Ross A Baker, Robert McQuade, Phyllis M Salzman, Raymond Sanchez, Margaretta Nyilas, William Carson
OBJECTIVE: To evaluate the efficacy, safety, and tolerability of aripiprazole, a dopamine D2 receptor partial agonist, as maintenance treatment in adolescent outpatients with schizophrenia. METHOD: This was a multicenter, double-blind, placebo-controlled, randomized withdrawal design trial. Participants 13 to 17 years of age with a diagnosis of schizophrenia (DSM-IV-TR) were first cross-titrated from their other oral antipsychotic(s) (4-6 weeks), then stabilized (7-21 weeks) on oral aripiprazole 10 to 30 mg/d, and finally randomized 2:1 to continuation of oral aripiprazole or to placebo in a double-blind maintenance phase (≤52 weeks)...
September 2017: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/28817397/real-world-data-on-paliperidone-palmitate-for-the-treatment-of-schizophrenia-and-other-psychotic-disorders-a-systematic-review-of-randomized-and-nonrandomized-studies
#11
Robin Emsley, Eduard Parellada, Miquel Bioque, Berta Herrera, Teresa Hernando, Marta García-Dorado
The aim of this study was to perform a systematic review of the effects of 1-month paliperidone palmitate (PP1M) for the treatment of schizophrenia and related psychotic disorders in terms of outcomes reported in real-world evidence studies. A systematic review of real-world randomized and nonrandomized studies with PP1M was performed and is reported according to PRISMA guidelines. Comparative effectiveness data with oral antipsychotics indicate that PP1M has a lower likelihood of relapse-related events, including rehospitalization, and these differences are clinically relevant...
August 16, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28816926/feasibility-and-relevance-of-antipsychotic-safety-monitoring-in-children-with-tourette-syndrome-a-prospective-longitudinal-study
#12
Tamara Pringsheim, Josephine Ho, Justyna R Sarna, Tracy Hammer, Scott Patten
PURPOSE/BACKGROUND: Antipsychotics are efficacious for tics and are increasingly prescribed to children with behavioral disorders. Antipsychotics have important adverse effects, and systematic monitoring of drug safety is infrequently performed. The objectives of this study were to determine the feasibility of antipsychotic safety monitoring in children with Tourette Syndrome using a defined protocol and to evaluate the risk of adverse effects with chronic use. METHODS/PROCEDURES: A prospective longitudinal study of children prescribed antipsychotics was performed...
October 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28806385/a-naturalistic-comparison-of-methylphenidate-and-risperidone-monotherapy-in-drug-naive-youth-with-attention-deficit-hyperactivity-disorder-comorbid-with-oppositional-defiant-disorder-and-aggression
#13
Gabriele Masi, Azzurra Manfredi, Giulia Nieri, Pietro Muratori, Chiara Pfanner, Annarita Milone
BACKGROUND/PURPOSE: Attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) are frequently co-occurring in youth, but data about the pharmacological management of this comorbidity are scarce, especially when impulsive aggression is prominent. Although stimulants are the first-line medication for ADHD, second-generation antipsychotics, namely, risperidone, are frequently used. We aimed to assess effectiveness and safety of monotherapy with the stimulant methylphenidate (MPH) and risperidone in a consecutive sample of 40 drug-naive male youths diagnosed as having ADHD-combined presentation, comorbid with ODD and aggression, without psychiatric comorbidities, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria and a structured clinical interview (Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version)...
August 10, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28755878/hyperprolactinaemia-in-first-episode-psychosis-a-longitudinal-assessment
#14
John Lally, Olesya Ajnakina, Brendon Stubbs, Hugh R Williams, Marco Colizzi, Elena Carra, Sara Fraietta, Poonam Gardner-Sood, Kathryn E Greenwood, Zerrin Atakan, Valeria Mondelli, Khalida Ismail, Oliver Howes, David M Taylor, Shubalade Smith, David Hopkins, Robin M Murray, Fiona Gaughran
Little is known about hyperprolactinaemia (HPL) in first episode psychosis (FEP) patients. We investigated longitudinal changes in serum prolactin in FEP, and the relationship between HPL, and antipsychotic medication and stress. Serum prolactin was recorded in FEP patients at recruitment and again, 3 and 12months later. HPL was defined as a serum prolactin level >410mIU/L (~19.3ng/ml) for males, and a serum prolactin level >510mIU/L (~24.1ng/ml) for females. From a total of 174 people with serum prolactin measurements at study recruitment, 43% (n=74) had HPL, whilst 27% (n=21/78) and 27% (n=26/95) had HPL at 3 and 12months respectively...
July 27, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28740637/antipsychotic-induced-hyperprolactinemia-in-tourette-syndrome
#15
REVIEW
Judith J G Rath, Marlies E J Deen, Hessel van Houten, Sebastiaan F T M de Bruijn, Joop van Gerven, Dick Mul
For many years, Tourette syndrome (TS) was considered to be a rare disorder, but tics and TS are now recognized as fairly common childhood-onset conditions. Children and adolescents with TS are frequently treated with antipsychotics, either as monotherapy or in combination with psychostimulants, melatonin and selective serotonin reuptake inhibitors (SSRIs). Antipsychotics are most often used in schizophrenia and related psychotic disorders, and in these conditions hyperprolactinemia is one of the most common adverse effects associated with antipsychotics, occurring in 40-50% of patients...
July 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28736102/antipsychotic-drugs-for-the-acute-treatment-of-patients-with-a-first-episode-of-schizophrenia-a-systematic-review-with-pairwise-and-network-meta-analyses
#16
Yikang Zhu, Marc Krause, Maximilian Huhn, Philipp Rothe, Johannes Schneider-Thoma, Anna Chaimani, Chunbo Li, John M Davis, Stefan Leucht
BACKGROUND: The first episode of schizophrenia is a pivotal phase of this debilitating illness. Which drug to use remains controversial without a summary of all direct or indirect comparisons of drugs. We did a systematic review with pairwise and network meta-analyses of efficacy and tolerability. METHODS: We searched MEDLINE, Embase, PsycINFO, Cochrane Library, PubMed, Biosis, and ClinicalTrials.gov for randomised controlled trials of antipsychotics for the acute treatment of first-episode schizophrenia, published up to Nov 17, 2016...
July 20, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28721051/effectiveness-of-amisulpride-in-chinese-patients-with-predominantly-negative-symptoms-of-schizophrenia-a-subanalysis-of-the-escape-study
#17
Ying Liang, Xin Yu
BACKGROUND: Effective management strategies for the negative symptoms of schizophrenia remain an unmet need, and data on the use of antipsychotics in this population are scarce, particularly in Chinese patients. Therefore, we investigated amisulpride for the treatment of Chinese patients with predominantly negative symptoms of schizophrenia. METHODS: This post hoc subanalysis of the prospective Effectiveness and Safety of Amisulpride in Chinese Patients with Schizophrenia (ESCAPE) study included adult Chinese patients with an International Classification of Diseases-10 diagnosis of schizophrenia and predominantly negative symptoms, who received amisulpride for 8 weeks...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28718324/physical-health-and-drug-safety-in-individuals-with-schizophrenia
#18
Tamara Pringsheim, Martina Kelly, Doug Urness, Michael Teehan, Zahinoor Ismail, David Gardner
BACKGROUND: While antipsychotic medications are the mainstay of therapy for individuals with schizophrenia and psychotic disorders, their use is associated with adverse effects on physical health that require the attention and care of prescribers. METHODS: We used the ADAPTE process to adapt existing guideline recommendations from the National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) guidelines on the dosing of antipsychotics and antipsychotic polypharmacy, screening for adverse effects of antipsychotics, and management of metabolic and extrapyramidal side effects to the Canadian context...
September 2017: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/28692485/safety-and-tolerability-of-cariprazine-in-patients-with-acute-exacerbation-of-schizophrenia-a-pooled-analysis-of-four-phase-ii-iii-randomized-double-blind-placebo-controlled-studies
#19
Willie Earley, Suresh Durgam, Kaifeng Lu, István Laszlovszky, Marc Debelle, John M Kane
Cariprazine, a potent dopamine D3 and D2 receptor partial agonist antipsychotic with preferential binding to D3 receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from the four acute trials in the cariprazine schizophrenia clinical development program (NCT00404573; NCT00694707; NCT01104766; NCT01104779) was carried out using the overall safety population (all patients who received ≥1 dose of study drug) and modal daily dose subgroups (1...
November 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28689816/a-novel-role-for-dopamine-signaling-in-the-pathogenesis-of-bone-loss-from-the-atypical-antipsychotic-drug-risperidone-in-female-mice
#20
Katherine J Motyl, Megan Beauchemin, Deborah Barlow, Phuong T Le, Kenichi Nagano, Annika Treyball, Anisha Contractor, Roland Baron, Clifford J Rosen, Karen L Houseknecht
Atypical antipsychotic (AA) drugs, including risperidone (RIS), are used to treat schizophrenia, bipolar disorder, and autism, and are prescribed off-label for other mental health issues. AA drugs are associated with severe metabolic side effects of obesity and type 2 diabetes. Cross-sectional and longitudinal data also show that risperidone causes bone loss and increases fracture risk in both men and women. There are several potential mechanisms of bone loss from RIS. One is hypogonadism due to hyperprolactinemia from dopamine receptor antagonism...
October 2017: Bone
keyword
keyword
51269
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"